What is HC Wainwright’s Estimate for PVLA Q1 Earnings?

Palvella Therapeutics, Inc. (NASDAQ:PVLA) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings estimates for Palvella Therapeutics in a report issued on Wednesday, April 1st. HC Wainwright analyst A. Fein anticipates that the company will post earnings of ($0.89) per share for the quarter. HC Wainwright has a “Buy” rating and a $270.00 price objective on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for Palvella Therapeutics’ Q2 2026 earnings at ($1.02) EPS, Q3 2026 earnings at ($1.19) EPS and Q4 2026 earnings at ($1.30) EPS.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings data on Tuesday, March 31st. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.95) by ($0.13).

PVLA has been the subject of several other research reports. Craig Hallum initiated coverage on Palvella Therapeutics in a research note on Thursday, December 4th. They set a “buy” rating and a $175.00 price target for the company. TD Cowen reissued a “buy” rating on shares of Palvella Therapeutics in a report on Monday, February 2nd. Mizuho lifted their price target on Palvella Therapeutics from $205.00 to $250.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Truist Financial set a $210.00 price objective on shares of Palvella Therapeutics in a research note on Tuesday, February 24th. Finally, Chardan Capital boosted their price objective on Palvella Therapeutics from $210.00 to $240.00 and gave the company a “buy” rating in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $198.07.

Palvella Therapeutics Stock Down 3.4%

Palvella Therapeutics stock opened at $120.38 on Thursday. The stock has a market cap of $1.43 billion, a P/E ratio of -32.45 and a beta of -0.20. The company’s 50 day moving average price is $105.80 and its two-hundred day moving average price is $91.85. Palvella Therapeutics has a 52 week low of $18.23 and a 52 week high of $151.18.

Insider Activity

In other news, Director Elaine J. Heron acquired 2,400 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The stock was bought at an average price of $125.00 per share, with a total value of $300,000.00. Following the completion of the acquisition, the director directly owned 47,812 shares of the company’s stock, valued at approximately $5,976,500. The trade was a 5.28% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director George M. Jenkins bought 4,000 shares of Palvella Therapeutics stock in a transaction on Friday, February 27th. The shares were acquired at an average cost of $125.00 per share, with a total value of $500,000.00. Following the completion of the acquisition, the director owned 187,171 shares of the company’s stock, valued at $23,396,375. The trade was a 2.18% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Palvella Therapeutics

Several large investors have recently bought and sold shares of PVLA. Group One Trading LLC grew its position in Palvella Therapeutics by 151.5% in the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after acquiring an additional 200 shares in the last quarter. Archer Investment Corp bought a new position in shares of Palvella Therapeutics during the 3rd quarter valued at approximately $28,000. Russell Investments Group Ltd. purchased a new stake in Palvella Therapeutics during the 3rd quarter valued at $36,000. China Universal Asset Management Co. Ltd. purchased a new position in Palvella Therapeutics during the fourth quarter worth $167,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Palvella Therapeutics in the fourth quarter valued at $238,000. Institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.